Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 10519153 Fused imidazo-piperidine JAK inhibitors

Patent 10519153 was granted and assigned to Theravance on December, 2019 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent attributes

Patent Applicant

Current Assignee

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Date of Patent

December 31, 2019

Patent Application Number

16225473

Date Filed

December 19, 2018

Patent Citations

US Patent 10100049 JAK kinase inhibitor compounds for treatment of respiratory disease

US Patent 10208040 Fused imidazo-piperidine JAK inhibitors

Patent Citations Received

US Patent 12122773 Crystalline hydrate of a JAK inhibitor compound

0

US Patent 11299492 JAK kinase inhibitor compounds for treatment of respiratory disease

US Patent 11786517 Methods of treatment using a JAK inhibitor compound

US Patent 11878977 JAK inhibitors containing a 4-membered heterocyclic amide

0

US Patent 10836763 5 to 7 membered heterocyclic amides as JAK inhibitors

US Patent 10844057 Process for preparing JAK inhibitors and intermediates thereof

US Patent 10947229 Dimethyl amino azetidine amides as JAK inhibitors

US Patent 11254669 Fused imidazo-piperidine JAK inhibitors

...

Patent Primary Examiner

Laura L. Stockton

Patent abstract

The invention provides compounds of formula (I):

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10519153 Fused imidazo-piperidine JAK inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool